A recent study investigated CML patients on IFN-α therapy and found prolonged complete molecular response, a sought-after goal in CML therapy, and very low risk of relapse in comparison to patients treated with targeted therapy (Imatinib) (36). The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.